Share-based Payment Arrangement, Expense in USD of NovoCure Ltd from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NovoCure Ltd quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2013 to Q3 2025.
  • NovoCure Ltd Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $29,321,000.000, a 6.51% decline year-over-year.
  • NovoCure Ltd Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $147,773,000.000, a 28.8% increase year-over-year.
  • NovoCure Ltd annual Share-based Payment Arrangement, Expense for 2024 was $160,035,000.000, a 38.4% increase from 2023.
  • NovoCure Ltd annual Share-based Payment Arrangement, Expense for 2023 was $115,608,000.000, a 8.09% increase from 2022.
  • NovoCure Ltd annual Share-based Payment Arrangement, Expense for 2022 was $106,955,000.000, a 12.7% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NovoCure Ltd Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $147,773,000 $29,321,000 -$2,043,000 -6.5% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025
Q2 2025 $149,816,000 $26,143,000 -$5,687,000 -17.9% 01 Apr 2025 30 Jun 2025 10-Q 24 Jul 2025
Q1 2025 $155,503,000 $29,552,000 -$4,532,000 -13.3% 01 Jan 2025 31 Mar 2025 10-Q 24 Apr 2025
Q4 2024 $160,035,000 $62,757,000 +$45,319,000 +2.6% 01 Oct 2024 31 Dec 2024 10-Q 30 Oct 2025
Q3 2024 $114,716,000 $31,364,000 +$5,018,000 +19% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025
Q2 2024 $109,698,000 $31,830,000 -$910,000 -2.8% 01 Apr 2024 30 Jun 2024 10-Q 24 Jul 2025
Q1 2024 $110,608,000 $34,084,000 -$5,000,000 -12.8% 01 Jan 2024 31 Mar 2024 10-Q 24 Apr 2025
Q4 2023 $115,608,000 $17,438,000 -$12,344,000 -41.4% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025
Q3 2023 $127,952,000 $26,346,000 +$41,000 +0.16% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024
Q2 2023 $127,911,000 $32,740,000 +$6,917,000 +26.8% 01 Apr 2023 30 Jun 2023 10-Q 25 Jul 2024
Q1 2023 $120,994,000 $39,084,000 +$14,039,000 +56.1% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q4 2022 $106,955,000 $29,782,000 +$7,384,000 +33% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025
Q3 2022 $99,571,000 $26,305,000 +$547,000 +2.1% 01 Jul 2022 30 Sep 2022 10-Q 26 Oct 2023
Q2 2022 $99,024,000 $25,823,000 -$2,058,000 -7.4% 01 Apr 2022 30 Jun 2022 10-Q 27 Jul 2023
Q1 2022 $101,082,000 $25,045,000 +$6,182,000 +32.8% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 $94,900,000 $22,398,000 +$2,125,000 +10.5% 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024
Q3 2021 $92,775,000 $25,758,000 +$5,637,000 +28% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022
Q2 2021 $87,138,000 $27,881,000 +$9,111,000 +48.5% 01 Apr 2021 30 Jun 2021 10-Q 28 Jul 2022
Q1 2021 $78,027,000 $18,863,000 +$2,306,000 +13.9% 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022
Q4 2020 $75,721,000 $20,273,000 +$5,576,000 +37.9% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023
Q3 2020 $70,145,000 $20,121,000 +$5,783,000 +40.3% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021
Q2 2020 $64,362,000 $18,770,000 +$5,038,000 +36.7% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021
Q1 2020 $59,324,000 $16,557,000 +$6,908,000 +71.6% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021
Q4 2019 $52,416,000 $14,697,000 +$4,056,000 +38.1% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022
Q3 2019 $48,360,000 $14,338,000 +$3,859,000 +36.8% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020
Q2 2019 $44,501,000 $13,732,000 +$3,526,000 +34.5% 01 Apr 2019 30 Jun 2019 10-Q/A 02 Oct 2020
Q1 2019 $40,975,000 $9,649,000 +$1,129,000 +13.3% 01 Jan 2019 31 Mar 2019 10-Q/A 02 Oct 2020
Q4 2018 $39,846,000 $10,641,000 +$4,285,000 +67.4% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021
Q3 2018 $35,561,000 $10,479,000 +$1,850,000 +21.4% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019
Q2 2018 $33,711,000 $10,206,000 +$2,636,000 +34.8% 01 Apr 2018 30 Jun 2018 10-Q 25 Jul 2019
Q1 2018 $31,075,000 $8,520,000 +$3,959,000 +86.8% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019
Q4 2017 $27,116,000 $6,356,000 +$1,634,000 +34.6% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020
Q3 2017 $25,482,000 $8,629,000 +$3,003,000 +53.4% 01 Jul 2017 30 Sep 2017 10-Q 25 Oct 2018
Q2 2017 $22,479,000 $7,570,000 +$1,933,000 +34.3% 01 Apr 2017 30 Jun 2017 10-Q 26 Jul 2018
Q1 2017 $20,546,000 $4,561,000 -$895,000 -16.4% 01 Jan 2017 31 Mar 2017 10-Q 26 Apr 2018
Q4 2016 $21,441,000 $4,722,000 +$234,000 +5.2% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019
Q3 2016 $21,207,000 $5,626,000 +$2,698,000 +92.1% 01 Jul 2016 30 Sep 2016 10-Q 26 Oct 2017
Q2 2016 $18,509,000 $5,637,000 +$3,005,000 +1.1% 01 Apr 2016 30 Jun 2016 10-Q 27 Jul 2017
Q1 2016 $15,504,000 $5,456,000 +$3,644,000 +2% 01 Jan 2016 31 Mar 2016 10-Q 27 Apr 2017
Q4 2015 $11,860,000 $4,488,000 01 Oct 2015 31 Dec 2015 10-K 22 Feb 2018
Q3 2015 $2,928,000 +$1,723,000 +1.4% 01 Jul 2015 30 Sep 2015 10-Q 02 Nov 2016
Q2 2015 $2,632,000 01 Apr 2015 30 Jun 2015 10-Q 28 Jul 2016
Q1 2015 $1,812,000 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q3 2014 $1,205,000 01 Jul 2014 30 Sep 2014 10-Q 27 Oct 2015

NovoCure Ltd Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $160,035,000 +$44,427,000 +38.4% 01 Jan 2024 31 Dec 2024 10-Q 30 Oct 2025
2023 $115,608,000 +$8,653,000 +8.1% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025
2022 $106,955,000 +$12,055,000 +12.7% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025
2021 $94,900,000 +$19,179,000 +25.3% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024
2020 $75,721,000 +$23,305,000 +44.5% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023
2019 $52,416,000 +$12,570,000 +31.5% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022
2018 $39,846,000 +$12,730,000 +46.9% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 $27,116,000 +$5,675,000 +26.5% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 $21,441,000 +$9,581,000 +80.8% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019
2015 $11,860,000 +$7,236,000 +1.6% 01 Jan 2015 31 Dec 2015 10-K 22 Feb 2018
2014 $4,624,000 -$496,000 -9.7% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017
2013 $5,120,000 01 Jan 2013 31 Dec 2013 10-K 01 Mar 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.